CIK 0000109657
- Non-accelerated filer
- Smaller reporting company
GT Biopharma, Inc.
Sign in to watch- Ticker
- GTBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 941620407
- Phone
- +1 800-304-9888
- Business address
- 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO, CA, 94111
- Former names
- GT Biopharma, Inc., OXIS INTERNATIONAL INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-04 | Breen Michael Martin CEO and Director | Grant or award · Option to purchase Common Stock | +100,000 | 100,000 | ||
| 2025-09-04 | Breen Michael Martin CEO and Director | Grant or award · Option to purchase Common Stock | +100,000 | 100,000 | ||
| 2025-09-04 | Breen Michael Martin CEO and Director | Grant or award · Option to purchase Common Stock | +100,000 | 100,000 | ||
| 2023-08-11 | Breen Michael Martin Executive Chairman/Interim CEO | Grant or award | +200,000 | $0.29 | $57K | 856,218 |
| 2023-04-11 | Breen Michael Martin Executive Chairman/Interim CEO | Purchase | +50,000 | $0.50 | $25K | 656,218 |
| 2023-01-27 | Breen Michael Martin Exec Chairman and Interim CEO | Grant or award · Option to purchase Common Stock | +500,000 | 500,000 | ||
| 2022-07-15 | Breen Michael Martin Exec. Chair. and Interim CEO | Grant or award | +278,058 | 606,218 | ||
| 2022-07-15 | Breen Michael Martin Exec. Chair. and Interim CEO | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 | ||
| 2021-02-25 | Breen Michael Martin Director | Conversion | +40,243 | $3.40 | $137K | 318,301 |
| 2021-02-25 | Breen Michael Martin Director | Conversion | +9,859 | $3.40 | $34K | 328,160 |
| 2021-02-25 | Breen Michael Martin Director | Conversion · 10% Senior Convertible Debenture | −100,000 | 0 | ||
| 2021-02-25 | Breen Michael Martin Director | Conversion · 10% Senior Convertible Debenture | −30,000 | 0 | ||
| 2021-02-16 | Breen Michael Martin Director | Grant or award | +278,058 | 278,058 | ||
| 2021-02-16 | Breen Michael Martin Director | Grant or award · Option to purchase Common Stock | +50,000 | 50,000 |
Page 1 of 1 · 14 trades